Central America is emerging as a dynamic new arena within the Latin American healthcare market. Continual development of the industry, along with increased access to healthcare services, has boosted the growth of the industry. In 2015, the healthcare sector was valued at US $17.8 billion, while the Rx and consumer health industry reached a value of US $4 billion, growing at 5.6%. Within the region, two countries stand out for their potential to generate business opportunities: Costa Rica and Panama.
Would Costa Rica fit your growth strategy?
Did you know that Costa Rica is the largest country without armed forces?
Costa Rica is becoming an important emerging pharma market. Last year the total healthcare market in the country reached US $5 billion. The sector’s growth is promoted by public policies aimed at increasing access to healthcare services for the whole population.
Why does Costa Rica out stand within the Central American Region?
- Strongest economy
- Most stable political environment
- Easiest country to do business with
- Least corrupt country
- Strong public healthcare funding
These factors make it an appealing business opportunity for Pharma and OTC companies looking to expand into this Region. Life expectancy in Costa Rica is 79 years, comparable to that in most developed countries. Furthermore, over 75% of the population lives in urban areas, which eases access to healthcare, OTC and Rx drugs.
The pharma and OTC market is dominated by multinational and local Pharma and OTC companies such as Bayer, Merck, Sanofi, Stein, and Gutis, among others.
Lastly, access to information, as well as the adoption of healthier lifestyles among the population, is encouraging the use of consumer health products, which will in turn lead to growth in the OTC industry. Nonetheless, consumer behavior is typically influenced by strong relations with local retailers; it is therefore important to work with the right local partners.
Despite the potential of the country in the Central American region, a successful entry strategy requires a comprehensive understanding of the local market, the competitor landscape, and the regulatory environment. We at CPC have the experience in healthcare consulting to guide you in this process. Contact us to help you find the winning entry strategy.
Related Posts
Quit Smoking Drugs Market 2030: Growth Forecast & Opportunities
Explore the global Quit Smoking Drugs Market 2026, projected to reach USD 90.73 billion by 2030. Discover key Rx & OTC trends, growth drivers, and international market entry opportunities.
Thailand & Vietnam Rx & OTC Market: USD 30.5B by 2040
Thailand and Vietnam could form a USD 30.5 billion Rx & OTC market by 2040. Regulatory routes and pharmacy structures will be key to capturing this growth.
EAEU GMP Inspections Are Entering a New Phase: What Pharma & OTC Manufacturers Need to Prepare For
EAEU GMP inspections are evolving as the common market enters its post-transition phase. Manufacturers should prepare for new sterile-production requirements, risk-based oversight and stricter inspection readiness.



